ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2026
Characteristics of Youth With Type 2 Diabetes Prescribed Sodium-Glucose Cotransporter-2 Inhibitors Surrounding FDA Approval at an Academic Pediatric Medical Center.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSodium-glucose cotransporter-2 inhibitors (SGLT2i) were approved by the United States Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus (T2DM) in children aged 10 years and older on June 20, 2023. We describe SGLT2i prescribing trends among all specialties at a quaternary care pediatric medical center surrounding the approval of empagliflozin, then identify characteristics of patients with T2DM associated with a higher likelihood of SGLT2i prescription by pediatric endocrinologists.
methodsWe compared the total number of new SGLT2i prescriptions sent by all specialties before and after FDA approval of empagliflozin, between July 1, 2022, and June 30, 2024. We then identified children aged 10 years and older with T2DM who were newly prescribed an SGLT2i by pediatric endocrinologists. Demographic and clinical characteristics were compared with those of children with T2DM not prescribed SGLT2i.
resultsThe number of SGLT2i prescriptions sent by pediatric endocrinologists increased, and the top prescribing specialty shifted from Cardiology to Endocrinology. Increasing glycosylated hemoglobin (HbA1c) was associated with higher odds of SGLT2i prescription (OR 1.2 [95% CI, 1.1-1.3]; p < 0.001) regardless of empagliflozin approval status, low-density lipoprotein cholesterol, or urine microalbumin/creatinine ratio. Those prescribed SGLT2i before FDA approval were older, male, more frequently on insulin, and less frequently on metformin. These differences between groups were not seen post-approval.
conclusionsSGLT2is were more likely to be prescribed for youth with higher HBA1c by pediatric endocrinologists. The presence of risk factors for cardiovascular or renal disease was less important in the decision to prescribe SGLT2i, despite their reno- and cardioprotective effects in adults. Prospective and qualitative data would be useful in further understanding prescribing practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.